These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37126990)

  • 21. A validated prognostic classifier for
    Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
    Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
    Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.
    Javed S; Benoist S; Devos P; Truant S; Guimbaud R; Lièvre A; Sefrioui D; Cohen R; Artru P; Dupré A; Bachet JB; de la Fouchardière C; Ploquin A; Turpin A
    World J Surg Oncol; 2022 Apr; 20(1):131. PubMed ID: 35461290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
    Kopetz S; Desai J; Chan E; Hecht JR; O'Dwyer PJ; Maru D; Morris V; Janku F; Dasari A; Chung W; Issa JP; Gibbs P; James B; Powis G; Nolop KB; Bhattacharya S; Saltz L
    J Clin Oncol; 2015 Dec; 33(34):4032-8. PubMed ID: 26460303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-based Screening for
    Chu JE; Johnson B; Kugathasan L; Morris VK; Raghav K; Swanson L; Lim HJ; Renouf DJ; Gill S; Wolber R; Karsan A; Kopetz S; Schaeffer DF; Loree JM
    Clin Cancer Res; 2020 Sep; 26(17):4599-4605. PubMed ID: 32571791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer.
    Shimada Y; Muneoka Y; Nagahashi M; Ichikawa H; Tajima Y; Hirose Y; Ando T; Nakano M; Sakata J; Kameyama H; Takii Y; Ling Y; Okuda S; Takabe K; Wakai T
    Sci Rep; 2019 Feb; 9(1):2466. PubMed ID: 30792536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
    Atreya CE; Greene C; McWhirter RM; Ikram NS; Allen IE; Van Loon K; Venook AP; Yeh BM; Behr SC
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1536-1543. PubMed ID: 27956538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
    Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
    J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
    Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
    Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the therapy of BRAF
    Jin Z; Sinicrope FA
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
    [No Abstract]   [Full Text] [Related]  

  • 36. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer.
    Prasanna T; Wong R; Price T; Shapiro J; Tie J; Wong HL; Nott L; Roder D; Lee M; Kosmider S; Jalali A; Burge M; Padbury R; Maddern G; Carruthers S; Moore J; Sorich M; Karapetis CS; Gibbs P; Yip D
    Curr Probl Cancer; 2021 Feb; 45(1):100637. PubMed ID: 32826083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
    Osumi H; Shinozaki E; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Takahari D; Ooki A; Suzuki T; Ota Y; Nakayama I; Chin K; Miki Y; Yamaguchi K
    Int J Cancer; 2019 Nov; 145(9):2488-2495. PubMed ID: 30963570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF
    Gourdin G; Chotel L; de la Fouchardière C
    Adv Ther; 2023 Aug; 40(8):3281-3290. PubMed ID: 37316651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.
    Tran B; Kopetz S; Tie J; Gibbs P; Jiang ZQ; Lieu CH; Agarwal A; Maru DM; Sieber O; Desai J
    Cancer; 2011 Oct; 117(20):4623-32. PubMed ID: 21456008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.